FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4322772022> ?p ?o ?g. }

• W4322772022 endingPage "01" @default.
• W4322772022 startingPage "OT2" @default.
• W4322772022 abstract "Abstract Background: Populations of African ancestry are underrepresented in global oncology clinical trials resulting in paucity of data on safety and efficacy of cancer medicines in vulnerable Black populations. The ARETTA clinical trial was initiated by the Nigerian Breast Cancer Study Team in partnership with the University of Chicago Comprehensive Cancer Center to build local capacity for biomarker informed clinical trials and translational breast cancer research. ARETTA is a pragmatic single-arm, phase II clinical trial to optimize therapy and determine the safety and efficacy of neoadjuvant taxotere and trastuzumab in women with HER2-positive breast cancer. The study sought to 1) determine the pathological complete response (pCR) rate of patients with early stage breast cancer to neoadjuvant docetaxel and subcutaneous trastusumab 2) develop the capacity of investigators in Nigeria to improve quality of care through participation in oncology clinical trials using upgraded facilities and trained personnel and 3) determine accrual rate and retention of participants. Methods: Inclusion criteria include treatment naïve women aged 18 years to 70 years with HER-2 positive breast cancer stages II-IIIC (AJCC). Eligible participants receive four cycles of docetaxel 75mg/m2 and trastuzumab every 3 weeks. Those with incomplete clinical response by breast ultrasound volume measurements receive 3 additional cycles of chemotherapy; cyclophosphamide 600mg/m2, epirubicin 90mg/m2 and 5-fluorouracil 600mg/m2 every 3 weeks before re-evaluation for surgery. All participants receive a fixed dose of sub-cutaneous Herceptin (600mg) every 3 weeks (total of 18 doses). The primary endpoint is pCR rate. Secondary objectives are to evaluate invasive disease-free survival (iDFS), the pattern of response and mechanisms of resistance to treatment based on genomic markers, the pharmacokinetics of Herceptin SC, quality of life, and adverse event rates, including cardiac toxicity. Planned enrollment is 47 evaluable patients, which will provide 90% power to test the null hypothesis that the pCR rate is 20% versus a 40% alternative (one-sided alpha=0.05). More protocol details can be found at ClinicalTRial.gov NCT03879577 and JCO Glob Oncol2020 doi: 10.1200/GO.20.00043 Progress: The study has met its primary endpoint and will be closed to accrual by the time of the meeting. Results will be submitting as Late Breaking before the meeting Citation Format: Atara Ntekim, Adenike Adeniji-Sofoluwe, Abiola Ibraheem, Anthonia Sowunmi, Ayorinde Folasire, Thomas Olajide, Olalekan Olasehinde, Akinwunmi Komolafe, AbdulRazzak Lawal, Foluso Omodele, Ayodele Sanni, Mustapha Ajani, Olayinka Kotila, Sharifat Folorunsho, Tonyin Aniagwu, Adewumi Alabi, Abiodun Popoola, Chioma Asuzu, Adetola Daramola, Chinedum Babalola, Theodore Karrison, Fatimah Abdulkareem, Olufunmilayo I. Olopade. Assessing Response to neoadjuvant Taxotere and TrAstuzumab in Nigerian women with HER2-positive breast cancer (ARETTA) [abstract]. In: Proceedings of the 2022 San Antonio Breast Cancer Symposium; 2022 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2023;83(5 Suppl):Abstract nr OT2-21-01." @default.
• W4322772022 created "2023-03-03" @default.
• W4322772022 creator A5011985483 @default.
• W4322772022 creator A5013179907 @default.
• W4322772022 creator A5014674961 @default.
• W4322772022 creator A5015053533 @default.
• W4322772022 creator A5015776693 @default.
• W4322772022 creator A5019748918 @default.
• W4322772022 creator A5020438669 @default.
• W4322772022 creator A5022648004 @default.
• W4322772022 creator A5022805076 @default.
• W4322772022 creator A5031659516 @default.
• W4322772022 creator A5037092830 @default.
• W4322772022 creator A5038171309 @default.
• W4322772022 creator A5039599101 @default.
• W4322772022 creator A5047496831 @default.
• W4322772022 creator A5053324144 @default.
• W4322772022 creator A5057209864 @default.
• W4322772022 creator A5065205070 @default.
• W4322772022 creator A5068557282 @default.
• W4322772022 creator A5076361050 @default.
• W4322772022 creator A5077120293 @default.
• W4322772022 creator A5080301991 @default.
• W4322772022 creator A5082796784 @default.
• W4322772022 creator A5088900696 @default.
• W4322772022 date "2023-03-01" @default.
• W4322772022 modified "2023-09-26" @default.
• W4322772022 title "Abstract OT2-21-01: Assessing Response to neoadjuvant Taxotere and TrAstuzumab in Nigerian women with HER2-positive breast cancer (ARETTA)" @default.
• W4322772022 doi "https://doi.org/10.1158/1538-7445.sabcs22-ot2-21-01" @default.
• W4322772022 hasPublicationYear "2023" @default.
• W4322772022 type Work @default.
• W4322772022 citedByCount "0" @default.
• W4322772022 crossrefType "journal-article" @default.
• W4322772022 hasAuthorship W4322772022A5011985483 @default.
• W4322772022 hasAuthorship W4322772022A5013179907 @default.
• W4322772022 hasAuthorship W4322772022A5014674961 @default.
• W4322772022 hasAuthorship W4322772022A5015053533 @default.
• W4322772022 hasAuthorship W4322772022A5015776693 @default.
• W4322772022 hasAuthorship W4322772022A5019748918 @default.
• W4322772022 hasAuthorship W4322772022A5020438669 @default.
• W4322772022 hasAuthorship W4322772022A5022648004 @default.
• W4322772022 hasAuthorship W4322772022A5022805076 @default.
• W4322772022 hasAuthorship W4322772022A5031659516 @default.
• W4322772022 hasAuthorship W4322772022A5037092830 @default.
• W4322772022 hasAuthorship W4322772022A5038171309 @default.
• W4322772022 hasAuthorship W4322772022A5039599101 @default.
• W4322772022 hasAuthorship W4322772022A5047496831 @default.
• W4322772022 hasAuthorship W4322772022A5053324144 @default.
• W4322772022 hasAuthorship W4322772022A5057209864 @default.
• W4322772022 hasAuthorship W4322772022A5065205070 @default.
• W4322772022 hasAuthorship W4322772022A5068557282 @default.
• W4322772022 hasAuthorship W4322772022A5076361050 @default.
• W4322772022 hasAuthorship W4322772022A5077120293 @default.
• W4322772022 hasAuthorship W4322772022A5080301991 @default.
• W4322772022 hasAuthorship W4322772022A5082796784 @default.
• W4322772022 hasAuthorship W4322772022A5088900696 @default.
• W4322772022 hasConcept C121608353 @default.
• W4322772022 hasConcept C126322002 @default.
• W4322772022 hasConcept C143998085 @default.
• W4322772022 hasConcept C203092338 @default.
• W4322772022 hasConcept C2779786085 @default.
• W4322772022 hasConcept C2780835546 @default.
• W4322772022 hasConcept C2781190966 @default.
• W4322772022 hasConcept C530470458 @default.
• W4322772022 hasConcept C535046627 @default.
• W4322772022 hasConcept C71924100 @default.
• W4322772022 hasConceptScore W4322772022C121608353 @default.
• W4322772022 hasConceptScore W4322772022C126322002 @default.
• W4322772022 hasConceptScore W4322772022C143998085 @default.
• W4322772022 hasConceptScore W4322772022C203092338 @default.
• W4322772022 hasConceptScore W4322772022C2779786085 @default.
• W4322772022 hasConceptScore W4322772022C2780835546 @default.
• W4322772022 hasConceptScore W4322772022C2781190966 @default.
• W4322772022 hasConceptScore W4322772022C530470458 @default.
• W4322772022 hasConceptScore W4322772022C535046627 @default.
• W4322772022 hasConceptScore W4322772022C71924100 @default.
• W4322772022 hasIssue "5_Supplement" @default.
• W4322772022 hasLocation W43227720221 @default.
• W4322772022 hasOpenAccess W4322772022 @default.
• W4322772022 hasPrimaryLocation W43227720221 @default.
• W4322772022 hasRelatedWork W1979057726 @default.
• W4322772022 hasRelatedWork W2066747782 @default.
• W4322772022 hasRelatedWork W2068953208 @default.
• W4322772022 hasRelatedWork W2069548442 @default.
• W4322772022 hasRelatedWork W2274356170 @default.
• W4322772022 hasRelatedWork W2379981061 @default.
• W4322772022 hasRelatedWork W3118368214 @default.
• W4322772022 hasRelatedWork W4225868084 @default.
• W4322772022 hasRelatedWork W4252577211 @default.
• W4322772022 hasRelatedWork W4206891336 @default.
• W4322772022 hasVolume "83" @default.
• W4322772022 isParatext "false" @default.
• W4322772022 isRetracted "false" @default.
• W4322772022 workType "article" @default.